Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$201.20 USD

201.20
7,194,067

-0.48 (-0.24%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $201.20 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) Beats Q4 Earnings and Revenue Estimates

Merck (MRK) delivered earnings and revenue surprises of 3.85% and 0.65%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?

Smart Beta ETF report for NOBL

Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints

Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country.

Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates

Pfizer (PFE) delivered earnings and revenue surprises of 10.68% and 0.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) Stock Moves -0.43%: What You Should Know

AbbVie (ABBV) closed at $145.65 in the latest trading session, marking a -0.43% move from the prior day.

Eli Lilly (LLY) Lymphoma Candidate Pirtobrutinib Gets FDA Nod

The FDA approves Eli Lilly's Jaypirca (pirtobrutinib) under an accelerated approval pathway as a treatment for mantle cell lymphoma (MCL).

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $148.55, marking a -0.7% move from the previous day.

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $152.83, marking a -0.5% move from the previous day.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Zacks Market Edge Highlights: EXAS, ZM, TSLA, ABBV, ZOM

EXAS, ZM, TSLA, ABBV, ZOM have been highlighted in this Market Edge article.

Tracey Ryniec headshot

The Stocks Behind 2022's Popular ETFs

What stocks do popular ETF managers like Cathie Wood own in their portfolios?

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $159.64, moving -1.25% from the previous trading session.

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

CytomX (CTMX) Up 55% on Strategic Partnership With Moderna

CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $162.38, marking a +0.48% move from the previous day.

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer (PFE) Pentavalent Meningitis Jab BLA Gets FDA Acceptance

The FDA assigns a standard review to Pfizer's (PFE) BLA for pentavalent meningococcal vaccine candidate (MenABCWY), with a decision expected in October 2023.

The Zacks Analyst Blog Highlights AbbVie, PepsiCo, Oracle, HSBC Holdings and The Progressive

AbbVie, PepsiCo, Oracle, HSBC Holdings and The Progressive are part of the Zacks top Analyst Blog.

AbbVie (ABBV) Stock Moves -0.07%: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $162.99, moving -0.07% from the previous trading session.

Derek Lewis headshot

3 Dividend Kings Nicely Suited for Income Investors

Dividend Aristocrats, companies that have increased their dividend payouts for at least 25 consecutive years, are popular targets among income investors. However, a step above is the elite Dividend Kings group.